Alliances and Partnerships, Business, Free News Articles

Pure Transplant Solutions, LLC and Vall d’Hebron University Hospital Announce Research Collaboration

AUSTIN, Texas -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with Vall d'Hebron Barcelona Hospital Campus to develop new technologies for B-cell monitoring in transplant rejection.

The research is being led by Drs. Oriol Bestard and Rico Buchli and focuses on the detection of alloreactive memory B cells for pre-transplant risk stratification and post-transplant monitoring. Recognition of non-self HLA gives rise to the formation of HLA-specific memory B cells which precede circulating HLA antibodies. Importantly, such HLA-specific memory B cells can be present even in the absence of detectable serum antibodies, being an additional rejection risk factor in transplantation. Memory B cells are responsible for immunological recall responses by differentiating into antigen-specific antibody-producing cells upon re-encounter with a miss-matched antigen.

"This collaboration with PTS validates the tremendous need for appropriate and routinely applicable assays to detect and visualize the presence and HLA specificity of alloreactive memory B cells in solid organ transplant patients, which may ultimately help improve current alloimmune-risk stratification," Dr. Bestard stated.

"Today, the immunological risk of an individual transplant patient is mainly assessed by detection of HLA antibodies in the serum, which are produced by long lived bone marrow-residing plasma cells. At PTS, we envision that in addition to serum HLA antibody detection, HLA-specific memory B cell assays will serve as supplemental tools to determine risk factors and help improve individual patient management," said Dr. Buchli.

Steve Mayer MD, Chief Medical Officer at PTS stated, "We're very excited about the potential of this technology because it allows a very early diagnostic view of an individual's risk of rejection before any graft damage has occurred. Also, the technology is likely to have a significant impact on clinical utility with high predictive values."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: https://www.puretransplant.com/.

About Pure Protein, LLC

Pure Protein, L.L.C. is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its ecommerce website, https://www.hlaprotein.com/, Pure Protein offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About Vall d'Hebron Barcelona Hospital Campus

We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management. The Vall d'Hebron Barcelona Hospital Campus is the combination of our five entities: the Vall d'Hebron University Hospital, the Vall d'Hebron Research Institute (VHIR), the Vall d'Hebron Oncology Institute (VHIO), the Multiple Sclerosis Center of Catalonia (CEMCAT) and the Autonomous University of Barcelona.

We are constantly in touch with patients; our starting point is the challenges they present in our day-to-day work to continue to innovate and find new diagnostic methods and treatments. The talented team that has made us a leading institution allows us to work towards attracting excellence and training the best professionals in clinical practice.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Free News Articles

Pure Transplant Solutions, LLC and Oxford Immunotec, Ltd. Announce Exclusive Sublicense Agreement to Support Commercialization of Novel B Cell Measurement Assay for Early Detection of Tissue Injury and Prevention of Organ Rejection

AUSTIN, Texas -- Pure Transplant Solutions, LLC (PTS), a developer of novel HLA based transplant diagnostics, and Oxford Immunotec, Ltd. (OI), a global diagnostics company part of PerkinElmer Inc., today announce an exclusive sublicense agreement in which PTS will obtain exclusive commercial rights to issued patents protecting a novel assay originally developed by Dr. Oriol Bestard, M.D., Ph.D., that measures antibody-secreting B cells. Oxford Immunotec exclusively licensed the patented technology in 2015 from the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona, Spain, where Dr. Bestard performed his research.

"We are thrilled to add this assay to our portfolio of diagnostic solutions," said Blake Harlan, President of Pure Transplant Solutions. "This assay, when combined with our proprietary HLA tetramer technology, offers a powerful new diagnostic tool for transplant physicians that we expect will improve patient care and extend graft life."

"We are excited about the potential for Pure Transplant Solutions to apply our B-Cell assay technology to new diagnostic solutions in transplant medicine," commented Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec.

The enabling results of the B cell measuring technology were originally published in The Kidney International in a study co-authored by Dr. Bestard and showed the efficacy of the B cell technology in identifying patients at high risk for rejection that were not identified by other serological tests. The 70-patient study included patients on a waiting list for kidney transplantation as well as kidney transplant recipients undergoing antibody-mediated rejection.

Independently, PTS has continued to expand its portfolio of soluble HLA reagents including monomers and tetramers. Today, PTS has one of the largest selections of Class I and Class II proteins which are offered to researchers for Research Use Only through the company's website http://www.hlaprotein.com/.

When used with original assay technology, the combined assay offers a powerful and enhanced diagnostic tool that is complementary to existing assays such as the Panel of Reactive Antibodies (PRA) test and the Donor Specific Antibody (DSA) test, which represent the standard of care for the assessment of the likelihood of an antibody-driven rejection event in transplant patients. The PRA and DSA tests depend on the identification of antibody levels to foreign Human Leucocyte Antigens (HLA) in the blood. Because these levels fluctuate or the antibodies disappear entirely for various reasons, patients at-risk for rejection are often missed.

The enhanced B cell addresses this problem by directly measuring the underlying B cells themselves, which have the potential to rapidly react to a donor organ and produce antibodies that contribute to acute rejection. By measuring these specific foreign HLA antibody-secreting B cells, the test is able to identify such sensitized patients regardless of the presence of circulating antibodies, potentially identifying at-risk patients missed by the PRA and DSA tests.

NOTES:

[1]Lúcia M et al. Preformed circulating HLA-specific memory B cells predict high risk of humoral rejection in kidney transplantation. Kidney International advance online publication, July 15, 2015; doi:10.1038/ki.2015.205

Definitions

HLA - Human Leucocyte Antigens - Proteins on the surface of cells that are responsible for regulation of the immune system and particularly responsible for the ability of the immune system to recognize self from non-self.

PRA Test - Panel of Reactive Antibody test - An immunological laboratory blood test that assesses the extent to which the patient on the transplant waiting list will react, via pre-existing antibodies, to non-self. Any PRA score indicates that the patient has a higher risk of antibody mediated graft rejection.

DSA Test - Donor Specific Antibody test - An immunological laboratory blood test that assesses the presence of antibodies in the transplant patient that are generated specifically against the donor's HLA type. The presence of DSA indicates that the patient has a higher risk of antibody-mediated allograft rejection. Pre-transplant, the DSA test indicates which donor HLA types may not be tolerated or would carry a higher risk of antibody-mediated graft rejection. Post-transplant, persistence or appearance of DSA may indicate a high risk of ongoing or future antibody mediated graft rejection.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Learn more: https://www.puretransplant.com/.

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, www.hlaprotein.com, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About Oxford Immunotec, Ltd.

Oxford Immunotec is a global diagnostics company and part of PerkinElmer Inc. We bring energy and invention to a world in need of diagnostic truth. We are uniquely placed as the only company in the world offering regulated ELISPOT assays for T cell measurement, with approval around the globe. Our leading product, the T-SPOT.TB test, is used for diagnosing infection with Tuberculosis, the world's largest cause of death from infectious disease. Oxford Immunotec is an experienced manufacturer of IVD tests, operating under a fully audited Quality Management System, ensuring rigorous batch control. The company has manufactured in excess of 20 million clinical T cell tests for TB infection.

The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States (where it has received pre-market approval from the Food and Drug Administration), Europe (where it has obtained a CE mark), as well as Japan and China. The recently released T-SPOT.COVID test is CE marked in Europe for clinical use to detect the T cell immune response to SARS-CoV-2 (www.tspotcovid.com). Oxford Immunotec is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.

About PerkinElmer

PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 15,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at https://www.perkinelmer.com/.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Free News Articles

Pure Transplant Solutions, LLC Announces Research Collaboration with the Department of Surgery at the University of Cambridge

AUSTIN, Texas -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The University of Cambridge Abdominal Transplant Centre at Addenbrooke's Hospital, to develop new diagnostic strategies for DSA monitoring and characterization in transplantation.

The research is being led by Dr. Vasilis Kosmoliaptsis, Honorary Consultant Abdominal Transplant and HPB Surgeon, and Dr. Rico Buchli, Vice President Products and Services and Director of Research at PTS and its parent company, Pure Protein, LLC. The research project aims to investigate the relationship between alloantibody-HLA binding strength and the capacity of alloantibodies to mediate graft injury in solid organ transplantation, with the goal to develop and validate new HLA-antibody assays that will define the future thinking of antibody affinity in transplant rejection.

Dr. Kosmoliaptsis's group and collaborators have recently developed a novel immunoassay (microfluidic antibody affinity profiling) that enables quantification of antibody affinity and concentration directly in patient sera thus allowing clinical translation of this research for patient benefit. If successful, such data will potentially facilitate a new diagnostic tool to quantify alloantibody-mediated immunological risk that may enable improved access to transplantation, reduce the risk of humoral rejection, and improve transplant outcomes.

"Antibody affinity matters, and we believe that this work has the potential to transform clinical practice in transplantation," Dr. Kosmoliaptsis stated. "The provision of purified and naturally folded HLA reagents by PTS for use in our kinetics experiments provides an exciting opportunity to increase our understanding of the pathogenic potential of HLA-specific antibodies in the context of transplantation and to improve long-term transplant outcomes."

"This research will provide compelling new evidence supporting the role of DSA affinity assessment in risk stratification of donor-specific humoral responses. We foresee that this new insight into HLA antibody kinetics will provide new strategies and diagnostics that could help improve individual patient care and ultimately increase the lifespan of transplants," said Dr. Buchli.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation.

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, http://www.hlaprotein.com/, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aid in improving the design of vaccination and therapeutic targeting strategies.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Free News Articles, Surgery and Neurotechnology

Pure Transplant Solutions Announces Collaboration with Innobiochips to Develop Personalized Diagnostics for Post-Transplant Monitoring and Early Detection of Transplant Rejection

AUSTIN, Texas -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Innobiochips (IBC), a developer of innovative immunoassays and the SirYus™ diagnostic platform technology, to develop personalized HLA diagnostics that will detect and quantify donor specific antibodies (DSA's) in post-transplant settings and provide the basis for post-transplant monitoring and early detections of transplant rejection.

The research is being led by Innobiochips co-founders Drs. Vianney Souplet and Christophe Olivier, and Dr. Rico Buchli, VP of Products and Services at PTS. The collaboration aims to develop and validate new individualized, allele specific HLA-antibody diagnostics. The initial goals of the collaboration are to quickly develop the first commercial prototype and gather the data needed to validate the platform with leading community experts. The companies are optimistic that they will be able to rapidly provide a new portfolio of allele specific diagnostics to HLA lab directors, transplant clinicians and transplant patients that do not currently exist. These new diagnostics would enable personalized, easy to use, and quantifiable sequential monitoring of patient specific DSA levels, the result of which would provide a new pro-active window for clinicians to implement earlier graft saving interventions for transplant recipients.

"Between our two companies, we feel that we already have the ingredients needed to provide a new set of tools to those who care for transplant patients," Dr. Buchli stated. "Our proteins solve a number of important challenges on the serological side while the Innobiochips SirYus platform provides a very easy to use and elegant way to manufacture discrete, allele specific tests with the necessary controls, it really is a powerful combination."

"Over the past years, our companies have been exploring ways to combine our complementary technologies to create breakthrough diagnostics in the transplant market. PTS has the in-depth knowledge in HLA proteins and IBC has demonstrated that its technology is incredibly flexible and can enable as many as 144 serological assays at the same time in a single well, providing the transplantation departments an outstanding and new solution for HLA detection," Dr Souplet stated.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation.

Learn more: https://www.puretransplant.com/

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, www.hlaprotein.com, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About Innobiochips

Innobiochips is a diagnostic company committed to provide innovative multiplex immunoassays and aims to position its technology, SirYus™, as a new standard for In Vitro Diagnostics. As of today, Innobiochips has developed and produces products dedicated to transplantation and immunodeficiency and is partnering with several major players to incorporate the SirYus technology into larger IVD applications.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Free News Articles, Surgery and Neurotechnology

Pure Transplant Solutions Announces Collaboration with Northwestern University to Develop Novel Reagents for Enhanced Characterization of HLA DQ Antigens in Transplant Rejection

AUSTIN, Texas -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Northwestern University, a world leader in HLA DQ antigen research.

The focus of the collaboration is to develop and test novel HLA reagents created by PTS that may be used for enhanced analysis and characterization of DQ antigens, an HLA Class II type that is increasingly gaining importance in causing rejection in transplant patients.

The research is being led by Dr. Anat Tambur, Director of the Transplant Immunology Laboratory and Comprehensive Transplant Center at Northwestern University Feinberg School of Medicine, and Dr. Rico Buchli, VP of Products and Services at PTS.

"The Tambur lab at the Comprehensive Transplant Center, Northwestern University, Chicago, is focusing on understanding the immunogenicity of HLA-DQ antigens and its role in antibody-mediated rejection in solid organ transplantation," said Dr. Tambur. "Increasing evidence has demonstrated that DQ mismatches between transplant recipient and donor are the most common to induce de novo donor-specific antibodies (DSA). HLA-DQ antibodies are likely also the most detrimental to graft survival. Understanding the unique structural and molecular properties that make the HLA-DQ molecule so pathogenic may eventually help us better predict which mismatches will induce harmful antibody formation, and which are more permissible. This work requires availability of purified HLA-DQ and other HLA class II molecules, maintaining high physiologic accuracy of the three-dimensional structure. Our collaboration with Pure Transplant Solutions allows us to develop unique approaches to study the unique involvement of HLA-DQ in transplant immunology."

"In the last years, we have seen a re-emerging role of HLA-DQ in transplantation medicine with increasing evidence that DQ mismatches between transplant recipient and donor are most detrimental to graft survival," said Dr. Buchli. "Our panel of highly representative HLA-DQ alleles will help to drive novel research to prevent transplant rejection and to contribute to more insight into DSA responses and we are thrilled to be working with Dr. Tambur, a world leader in this field."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: www.puretransplant.com

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, www.hlaprotein.com, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Drugs and Pharmaceuticals, Free News Articles, Surgery and Neurotechnology

Pure Transplant Solutions Announces Collaboration with the University of Alabama at Birmingham to Develop Memory B Cell-Directed Diagnostics for HLA-Sensitized Patients

BIRMINGHAM, Ala. -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with The University of Alabama at Birmingham (UAB), a leading institution in transplant research, to develop a new class of transplant diagnostics aimed at the detection and identification of HLA-specific memory B cells which are poised to produce HLA-specific immunoglobulin injurious to transplanted grafts.

The research is being led by Dr. Frances Lund, Charles H. McCauley Professor and Chair Department of Microbiology, Dr. John Killian, resident in the Department of Surgery, and Dr. Rico Buchli, VP of Products and Services at PTS, and focuses on using PTS's newly created Class I and Class II biotinylated soluble HLA (sHLA) proteins to understand the breadth and specificity of HLA-reactive B cells in sensitized individuals. These proprietary HLA molecules can be utilized in standard flow cytometry workflows for easy processing and analysis that the parties hope will provide a new tool for clinicians and researchers to use when caring for transplant patients.

Almost all previous work on HLA sensitized individuals has relied upon assays that detect circulating anti-HLA antibodies. The goal is to determine the reactivities of HLA-reactive B cells in these sensitized patients and compare these reactivities to those that are present among circulating anti-HLA antibodies. Using panels of biotinylated HLA molecules in combination with various tetramerized fluorescent reagents allows the interrogation of the specific B cell receptors expressed by HLA-reactive B cells.

"Prevention of B cell activation and proliferation is crucial for the survival of a transplant patient. For patient monitoring, identifying the right approach to immune profiling at each stage of clinical development-including the later stages, when it is often considered impractical to include these approaches-may be critical for identifying predictors of rejection responses, or monitoring immunosuppression efficacy", said Dr. Buchli. "Flow cytometric analysis using our fluorescent tagged HLA products have the capabilities needed to meet the increased demands to detect, identify, and monitor HLA-specific memory B cells."

"Our research at the University of Alabama at Birmingham seeks to improve the success of organ transplants," said John Killian, Jr., M.D., a research resident in the UAB Department of Surgery. "One problem is that following pregnancy or transplant, patients form antibodies against non-self HLA molecules. These antibodies comprise a major barrier to transplantation, and they exacerbate gender and racial disparities for thousands of people who await a life-saving transplant. Thus, we want to understand the breadth and specificity of HLA-reactive memory B cells in sensitized women. Pure Protein's extensive selection of recombinant HLA molecules will be integral to our projects, allowing us to pair fluorescence-activated cell sorting of HLA-reactive B cells with subsequent analysis of recombinant-antibody specificities. An improved understanding of the phenotype and specificity of HLA-reactive B cells will offer new opportunities to diagnose and treat HLA sensitization."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: www.puretransplant.com

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, http://www.hlaprotein.com/, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About the University of Alabama Birmingham

Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham, a part of the University of Alabama System, is an internationally renowned research university and academic medical center with over $600 million in research awards annually, as well as Alabama's largest employer, with some 23,000 employees, and has an annual economic impact exceeding $7 billion on the state. The pillars of UAB's mission include education, research, innovation and economic development, community engagement, and patient care. Learn more at https://www.uab.edu/.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Free News Articles

Pure Transplant Solutions Announces Collaboration with King’s College London to Support NHS Funded GAMECHANgER-1 Clinical Trial for HLA Sensitized Patients with End Stage Renal Disease

AUSTIN, Texas -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with King's College London, a leading university providing world-class teaching and cutting-edge research, to support the Phase IIa GAMECHANgER-1 clinical trial.

The trial aims to determine whether adoptive transfer of regulatory T cells (Tregs) into HLA sensitised patients can suppress memory T and B cell responses against specific HLA antigens in order to extend the longevity of donor organs.

The collaborative research is being led by Dr. Anthony Dorling, Professor of Transplant Inflammation and Repair, and Honorary Consultant Nephrologist at the Centre for Nephrology, Urology, and Transplantation, and Dr. Rico Buchli, VP of Products and Services at PTS. The collaboration intends to investigate whether in vitro anti-HLA T & B cell responses in sensitized patients can be inhibited by an adoptive transfer of T regulatory cells. Under the Agreement, PTS will provide its proprietary soluble HLA (sHLA) molecules which will be used to trigger functional responses of patient cells in Fluorospot assays.

Furthermore, PTS will provide biotinylated sHLA for memory b-cell detection and characterization. Researchers hope that the results of the study will lead to a better understanding of immune tolerance, extend the duration of suppression of HLA-specific responses by Tregs and ultimately produce state-of-the-art immune therapeutics to control rejection.

"We feel that PTS has the fundamental ingredients needed to provide new sets of tools to those who care for transplant patients," Dr. Buchli stated. "Our proteins can solve a number of important challenges in DSA and B cell monitoring. With this collaboration, we are able to go beyond monitoring and help pave the way in generating immune therapeutics of the future."

"The group of highly sensitized dialysis patients that we'll be recruiting to GAMECHANgER-1 have difficulties getting a suitable kidney transplant and once transplanted suffer higher rates of rejection and complications associated with our current treatments for rejection," said Dr. Dorling. "This trial will determine whether patients' own regulatory T cells can be used to suppress immune memory responses against specific human leukocyte antigens (HLA), and if successful will pave the way for larger scale trials to determine if these regulatory cells can be used as therapy to prevent or minimise these problems in future. The HLA proteins provided by Pure Transplant Solutions are an essential tool used to tailor our immunemonitoring for individual patients, so I'm delighted to be partnering with the company to ensure a stable, long-term supply of these reagents. This trial offers a glimpse of how personalised medicine might help transform outcomes for this disadvantaged group of patients."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: http://www.puretransplant.com/

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website - http://www.hlaprotein.com/ - Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About King's College London

King's College London (King's) is one of the top 10 UK universities in the world (QS World University Rankings, 2018/19) and among the oldest in England. King's has more than 31,000 students (including more than 12,800 postgraduates) from some 150 countries worldwide, and some 8,500 staff. King's has an outstanding reputation for world-class teaching and cutting-edge research. In the 2014 Research Excellence Framework (REF), eighty-four per cent of research at King's was deemed 'world-leading' or 'internationally excellent' (3* and 4*).

Since its foundation, King's students and staff have dedicated themselves in the service of society. King's will continue to focus on world-leading education, research and service, and will have an increasingly proactive role to play in a more interconnected, complex world. Visit our website to find out more about Vision 2029, King's strategic vision for the next 12 years to 2029, which will be the 200th anniversary of the founding of the university.

World-changing ideas. Life-changing impact: https://www.kcl.ac.uk/news/spotlight

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Free News Articles

Pure Transplant Solutions, LLC and University Hospital Basel Announce Research Collaboration

AUSTIN, Texas -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The Transplantation Immunology & Nephrology Department of the University Hospital of Basel, to develop new diagnostics for DSA monitoring and characterization in transplant rejection.

The research is being led by Prof. Stefan Schaub, Senior Physician at the Kidney Transplant Center, Gideon Hönger, Senior Researcher within the Transplantation Immunology & Nephrology Department, and Dr. Rico Buchli, Director of Research at PTS and its parent company, Pure Protein, LLC. The research project aims to develop and validate new HLA-antibody affinity/avidity assays.

The initial goal of the collaboration is to gather data that supports the correlation of the measured DSA binding properties with clinical outcomes in renal allograft recipients. If successful, such data will potentially enable a new diagnostic tool delivering a numerical risk factor rating indicating the prospective severity of rejection by classifying individual DSA from 'very harmful' to 'likely harmless.'

"These non-modified and naturally folded HLA monomers of Pure Proteins are ideally suited as reaction partners for patient HLA antibodies and for our intended kinetic measurements," Mr. Hönger stated. "Several research colleagues reported high satisfaction regarding the overall quality and functionality of sHLA from Pure Protein," said Prof. Schaub.

"Today, the immunological risk of an individual transplant patient is mainly assessed by the detection of HLA antibodies and their specificity in serum using single antigen bead assays. We envision that in addition to these tests, we can develop methods to measure the kinetics of donor-specific HLA- antibody interactions with our HLA proteins. If successful, this will provide new insight into HLA antibody pathogenicity that could help improve individual patient care and ultimately increase the lifespan of transplants," said Dr. Buchli.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: http://www.puretransplant.com/.

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. (www.etibio.com) that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation. Visit: http://www.pureproteinllc.com/.

Through its new ecommerce website - http://www.hlaprotein.com/ - Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About University Hospital Basel

The University Hospital Basel is a tertiary hospital in northern Switzerland performing around 60-80 kidney transplantations per year. Further information can be found on the homepage of the hospital at https://www.unispital-basel.ch/en/ and on the clinic site at https://www.unispital-basel.ch/en/ueber-uns/bereiche/medizin/kliniken-institute-abteilungen/transplantation-immunology-nephrology/.

*LOGO link for media: https://www.Send2Press.com/300dpi/21-0127s2p-pure-transplant-300dpi.jpg

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.